Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcus Biosciences Inc
(NY:
RCUS
)
17.33
+0.07 (+0.41%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arcus Biosciences Inc
< Previous
1
2
3
4
5
Next >
Breaking Down Arcus Biosciences: 4 Analysts Share Their Views
August 09, 2024
Via
Benzinga
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences
July 08, 2024
Via
Benzinga
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
June 03, 2024
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 24, 2024
Via
Benzinga
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Navigating 5 Analyst Ratings For Arcus Biosciences
March 25, 2024
Via
Benzinga
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know
February 22, 2024
Via
Benzinga
Recap: Arcus Biosciences Q4 Earnings
February 21, 2024
Via
Benzinga
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
November 07, 2023
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
October 05, 2023
On Thursday, 369 companies hit new 52-week lows.
Via
Benzinga
Expert Ratings for Arcus Biosciences
October 03, 2023
Via
Benzinga
Where Arcus Biosciences Stands With Analysts
September 12, 2023
Via
Benzinga
Earnings Scheduled For February 21, 2024
February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Via
Benzinga
Preview: Arcus Biosciences's Earnings
February 20, 2024
Via
Benzinga
$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
February 01, 2024
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
Key Takeaways From Arcus Biosciences Analyst Ratings
January 30, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
January 30, 2024
We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today!
Via
InvestorPlace
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars
January 30, 2024
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy.
Via
Benzinga
What 9 Analyst Ratings Have To Say About Arcus Biosciences
November 08, 2023
Via
Benzinga
Arcus Biosciences: Q3 Earnings Insights
November 07, 2023
Via
Benzinga
5 Analysts Have This to Say About Arcus Biosciences
August 24, 2023
Via
Benzinga
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
August 23, 2023
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 23, 2023
Via
Benzinga
Why Grab Holdings Are Trading Higher By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
August 23, 2023
Gainers AgileThought, Inc. (NASDAQ: AGIL) jumped 85.5% to $0.3941. AgileThought recently posted a loss for the second quarter.
Via
Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
August 23, 2023
Roche provided an update from its study in lung cancer using an anti-TIGIT drug.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 23, 2023
Via
Benzinga
Why AMC Entertainment Shares Are Trading Lower By 21%; Here Are 20 Stocks Moving Premarket
August 23, 2023
Gainers BioNexus Gene Lab Corp. (NASDAQ: BGLC) shares gained 48.5% to $2.05 in pre-market trading after jumping 30% on Tuesday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
August 23, 2023
It's time for another dive into the biggest pre-market stock movers as we break down all of the biggest news on Wednesday!
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.